DB
UNCY icon

Danske Bank’s Unicycive Therapeutics UNCY Stock Holding History

Danske Bank’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7 Hold
1
– – ﹤0.01% 1095
2025
Q4 		$6 Hold
1
– – ﹤0.01% 1499
2025
Q3 		$4 Hold
1
– – ﹤0.01% 1448
2025
Q2 		$5 Buy
+1
New +$6 ﹤0.01% 1479

Other funds holding UNCY

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Danske Bank's UNCY Position: Q1 2026 in Review

Danske Bank held its Unicycive Therapeutics (UNCY) position steady in Q1 2026 at 1 share worth $7. The position accounts for ﹤0.01% of the portfolio, ranked #1095.

Danske Bank first reported a position in UNCY in Q2 2025 and has held it in 4 quarters since. 51 funds tracked by Wall St. Rank hold UNCY as of Q1 2026.

  • Danske Bank held 1 share of Unicycive Therapeutics worth $7 as of Q1 2026.
  • Danske Bank left its Unicycive Therapeutics share count unchanged in Q1 2026.
  • Unicycive Therapeutics made up ﹤0.01% of Danske Bank's portfolio in Q1 2026, its #1095 holding.
  • Danske Bank first reported a position in Unicycive Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 51 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q1 2026.

Based on Danske Bank's 13F filing for Q1 2026, filed 12 May 2026.